+44 20 3868 9735
In Acute Myeloid Leukemia (AML) patients, a diversity of clinical and hematological parameters has been examined for possible value in calculating treatment response and survival. The study was conducted at National Institute of Bone Diseases, Karachi (NIBD), Sind, Pakistan, a tertiary care and teaching hospital, affiliated with Liaquat University of Medical and Health Sciences, Jamshoro. This study included 107 cases of de novo AML, both male and female patients of ages between 10-60 years were selected randomly. The clinical features included fever, weakness, loss of weight, vomiting, bleeding gums, liver and spleen enlargement, lymph node enlargement. The Laboratory investigations included CBC (Complete Blood Count) specifically heamoglobin percentage, total leucocyte count, platelet count and blast count: peripheral blood smears, bone marrow aspiration biopsy, trephine biopsy, cytochemistry (Myeloperoxidase Staining, Immunohistochemistry (CD markers)) and DNA extraction for genetic sequencing. Percentage, validity and cumulative index were calculated of all parameters. It was found that about 70% of AML patients were adults and FAB subtype M2 of acute myeloid leukemia was more prevalent than other subtypes, followed by AML, M1.